Abstract
Carriership of coagulation factor V Leiden (FVL) is by far the most common thrombophilia in Western populations. FVL is caused by a single point mutation in the gene coding for coagulation factor V (FV) causing a lifelong procoagulatory state with an increased risk of venous thromboembolism (VTE) which might be fatal. It is believed that the mutation occurred in one person 21,000 years ago and today 3% to 15% of the Western populations are carriers. A potentially dangerous mutation such as FVL ought to be rare and should have been reduced, if not eradicated, by selection during the course of human evolution. Thus, FVL must confer the carriers with an evolutionary advantage in order to be so prevalent. Lower risk of profuse bleeding and increased fecundity might give carriers an advantage. In this paper we give an updated short background and discuss possible evolutionary advantages and disadvantages.
Keywords: Factor V Leiden, evolution, advantage, obstetric complications, bleeding, APC resistance.
Current Medicinal Chemistry
Title:On the Evolutionary Advantage of Coagulation Factor V Leiden (FVL)
Volume: 22 Issue: 32
Author(s): P.G. Lindqvist
Affiliation:
Keywords: Factor V Leiden, evolution, advantage, obstetric complications, bleeding, APC resistance.
Abstract: Carriership of coagulation factor V Leiden (FVL) is by far the most common thrombophilia in Western populations. FVL is caused by a single point mutation in the gene coding for coagulation factor V (FV) causing a lifelong procoagulatory state with an increased risk of venous thromboembolism (VTE) which might be fatal. It is believed that the mutation occurred in one person 21,000 years ago and today 3% to 15% of the Western populations are carriers. A potentially dangerous mutation such as FVL ought to be rare and should have been reduced, if not eradicated, by selection during the course of human evolution. Thus, FVL must confer the carriers with an evolutionary advantage in order to be so prevalent. Lower risk of profuse bleeding and increased fecundity might give carriers an advantage. In this paper we give an updated short background and discuss possible evolutionary advantages and disadvantages.
Export Options
About this article
Cite this article as:
Lindqvist P.G., On the Evolutionary Advantage of Coagulation Factor V Leiden (FVL), Current Medicinal Chemistry 2015; 22 (32) . https://dx.doi.org/10.2174/0929867322666151001121707
DOI https://dx.doi.org/10.2174/0929867322666151001121707 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of PEG-PLGA based Intravenous Low Molecular Weight Heparin (LMWH) Nanoparticles Intended to Treat Venous Thrombosis
Current Drug Delivery Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Randomized Clinical Stroke Trials in 2006
Current Vascular Pharmacology Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants
Cardiovascular & Hematological Disorders-Drug Targets Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Effects of Maternal Obesity on Maternal and Fetal Health
Current Women`s Health Reviews Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Chemical and Pharmacological Significance of Natural Guanidines from Marine Invertebrates
Mini-Reviews in Medicinal Chemistry Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Pharmacological and Cellular Therapies to Prevent Restenosis after Percutaneous Transluminal Angioplasty and Stenting
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non- Vitamin K Antagonists Oral Anticoagulants
Current Pharmaceutical Design Cerebrovascular Ultrasonography for Selecting Patients for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Thrombolytic Therapy in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Current Management of Neonatal Liver Tumors
Current Pediatric Reviews Heterogeneity of Synthetic Factor Xa Inhibitors
Current Pharmaceutical Design Ventilation/Perfusion SPECT - A New Challenge for Detection of Pulmonary Embolism. Can Multi Detector Computed Tomography Replace Lung Scintigraphy?
Current Medical Imaging Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews